Botulinum toxin therapy for neuropsychiatric disorders

Details Botulinum toxin therapy for neuropsychiatric disorders Botulinum toxin therapy for neuropsychiatric disorders

2007-06-12

2007-06-12

Navarro, Mark (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100

Reexamination Certificate

active

10806972

ABSTRACT:
Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.

REFERENCES:
patent: 5352447 (1994-10-01), Johnson et al.
patent: 5545617 (1996-08-01), Dartt et al.
patent: 5549884 (1996-08-01), Weinberger et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5843971 (1998-12-01), Boar et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6203794 (2001-03-01), Dolly et al.
patent: 6235289 (2001-05-01), Aoki et al.
patent: 6272370 (2001-08-01), Gillies et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6333037 (2001-12-01), Aoki et al.
patent: 6372226 (2002-04-01), Aoki et al.
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6429189 (2002-08-01), Borodic
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6451544 (2002-09-01), Giulian
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6475745 (2002-11-01), Giulian
patent: 6506399 (2003-01-01), Donovan
patent: 6524580 (2003-02-01), Donovan
patent: 6585970 (2003-07-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6645496 (2003-11-01), Aoki et al.
patent: 6645500 (2003-11-01), Halkier et al.
patent: 6716427 (2004-04-01), Donovan
patent: 6743424 (2004-06-01), Donovan
patent: 6827931 (2004-12-01), Donovan
patent: 6921538 (2005-07-01), Donovan
patent: 2003/0202990 (2003-10-01), Donovan et al.
patent: 2004/0018212 (2004-01-01), Aoki et al.
patent: 2004/0018213 (2004-01-01), Aoki et al.
patent: 2004/0062776 (2004-04-01), Voet
patent: 2005/0147626 (2005-07-01), Blumenfeld
patent: 10150415 (2003-05-01), None
patent: 0760681 (1999-01-01), None
patent: 99/55359 (1999-11-01), None
Auchus, Alexander P. et al, Neurology, vol. 45(2), Feb. 1995, p. 393.
Bassitt, D Pastore et al, Parmacopsychiatry, Jul. 2000, vol. 33(4) pp. 155(6).
Micheli. F et al, Clinical Neuropharmacology, vol. 21(3), pp. 199-200, 1998.
Rapaport, A et al, Movement disorders-official journal of the movement Disorder Society, Mar. 2000, vol. 15(2), pp. 352-355.
Burn, David J et al, Movement disorders, vol. 18(Suppl. 6), 2003, pp. S88-S95, Use of Functional imaging in Parkinsonism and dementia.
Wheeler, Anthony H., American Family Physician, vol. 55(2), p. 541+ (6), Feb. 1, 1997, Therapeutic uses of botulinum toxin. (includes patient information sheet).
Medline Plus Encyclopedia: Stress and anxiety definition, provided by the US National library and The National Institute of Health.
Thibaurt, F et al, L'Encephale (France, English abstract), Nov.-Dec. 1995, vol. 21(6), pp. 445-451, The dopamine transporter:characterization and physiopathologic implications.
Shabnam, Ghazi-Norri et al, Therapies for depression in Parkinson's disease, Cochrane database of systematic reviews, 2003, vol. 3, pCD003465 (abstract only).
Liberman, A, Managing the neuropsychiatric symptoms of Parkinson's disease, Neurology, vol. 50(6 suppl. 6), pp. S33-S38, Jun. 1998.
Fujimori, S et al, Neuropsychiatric disorders and GABA, Nihon shinkei seishin yakurigaku zasshi, Japanese Journal of psychopharmacology, Oct. 2004, vol. 24(5), pp. 265-271 (abstract only).
Sacco, K. A. et al, Journal of psychoparmacology, vol. 18(4), pp. 457-474, Dec. 2004, (abstract only).
Auchus, AP et al, Neurology, Feb. 1995, vol. 45(2), p. 393, Agitated behaviour relieved following treatment of cervical dystonia in dementia.
Micheli, Federico et al, Clinical Neurology, vol. 21(3), pp. 199-200, 1998, Hemifacial spasm triggered by vasodilatiors.
Bassitt, D. Pastore et al, Parmacopsychiatry, Jul. 2000, vol. 33(4), pp. 155(6).
Low, Phillip A, Current opinion in neurology, vol. 1 5(5), pp. 605-609, Oct. 2002.
Micheli, F et al, Clinical Neuropharmacology, vol. 21(3), pp. 199-200, 1998.
Kurata, K et al, Japanese Journal of Psychiatry and neurology, Mar. 1993, vol. 47(1), pp. 115-119.
Baltazar, Ge tal, European Journal of Cell Biology, vol. 79(12), apges 883-891, Dec. 2000.
Auchus, AP et al, Neurology, Feb. 1995, vol. 45(2), p. 393.
Micheli, F et al, Clinical neuropharmacology, May-Jun. 1998, vol. 21(3), pp. 199-200.
Velickovic, M et al, Drugs (New Zealand) 2001, vol. 61(13), apges 1921-1943.
Jimenez-Jimenez FJ et al, Drugs (New Zealand) 2001, vol. 61(15), pp. 2207-2220.
Egan, MF et al, Schizophrenia bulletin, 1997, vol. 23(4), pp. 583-609.
Auchus, Alexander P et al, Neurology, vol. 45 (2), Feb. 1995, p. 393.
Cereda, E., et al., Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders;Eur J Drug Metab Pharmacokinet; (3): 179-183.
Duggan, Michael J. et al., A survey of botulinum neurotoxin substrate expression in cells;Moving Disorders; 1995, May;10(3):376.
Sramka, M., et al., Long-term results in patients with stereotaxic surgery for psychopathological disorders,Bratisl. Lek. Listy, 93, 1992:7; pp. 364-366.
Cosgrove, G. Rees, et al., Cingulotomy in Psychosurgery, Chpt. 203, pp. 1965-1979; Stereotactic and Functional Neurosurgery, 1998, P. L. Gildenberg, Ed., McGraw-Hill Pub.
Hussain, E.S., et al., A cohort study of psychosurgery cases froma defined population, J. Neurol Neurosurg Psychiatry, Mar. 1988;51(3):345-52.
Kim, C.H., et al., Anterior cingulotomy for refractory obsessive-compulsive diso, Acta Psychiatr Scand. Apr. 2003; 107(4):283-90.
Kim, M.C., et al., Review of long-term results of stereotactic psychosurgery, Neurol Med Chir (Tokyo) Sep. 2002; 42(9):365-71.
Sramka, M., et al., Long-term resuls in patients with stereotaxic surgery for psychopathologic disorders, Bratisl Lek Listy Jul. 1992:93(7):364-6—English Abstract enclosed with Article.
Yoshimura, D.M., et al., Treatment of Hemifacial Spasm with Botulinum Toxin, Muscle Nerve 1992;15(9): 1045-9.
Yu Y.L., et al., Treatment of idiopathic hemifacial spasm with botulinum toxin, Acta Neurol Scand 1992;85(1):55-57.
Bejjani, B. et al., Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance, J. Neurosurg 92:615-625, Apr. 2000.
Bellezza, D., et al., Stereotactic Interstitial Brachytherapy, Text book of stereotactic and functional neurosurgery, McGraw-Hill, 1998, chp. 66, pp. 577-580.
Bigalke, H., et al., Tetanus Toxin and botulinum a toxin inhibit release and uptake of various transmitters, as studied with particulate preparations from rat brain and spinal cord, Naunyn-Schmiedeberg's Arch Pharmacol (1981) 316:244-251.
Bigalke, H., et al., Botulinum A neurotoxin inhibits non-cholinergic synaptic transmission in mouse spinal cord neurons in culture, Brain Research, 360 (1985) 318-324.
Brem, H., et al., The safety of interstitial chemotherapy with BCNU-loaded polymer follwed by radiation therapy in the treatment of newly diagnosied malignant gliomas: phase I trial, J. of Neuro-Oncology 26:111-123, 1995.
Brem, H., et al., Placebo-controlled trial saety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas, The Lancet, vol. 345, Apr. 22, 1995, pp. 1008-1012.
Burr Leiva, Daniel, The neurochemistry of mania: a hypothesis of etiology and a rationale for treatment, Prog. Neuro-Psychopharmacol & Biol. Psychiat. 1990, vol. 14, pp. 423-429.
Cereda, E., et al., Medicinal chemistry of muscarinic agonists for the treatment of dementia disorders, Eur J. Drug Metab Pharmacokinet 1994, Jul.-Sep.; 19(3): 179-83.
Clarke, P., et al., Innervation of substantia nigra neurons by cholinergic afferents from pedunculopontine nucleus in the rat: neuroanatomical and electrophysiological evidence, Neuroscience vol. 23, No. 3, pp. 1011-1019, 1987.
Cummings, J. L. et al., Alzheimer's disease: cognitive and behavioral pharmacotherapy, Connecticut Medicine, Sep. 1997, vol. 61, No.

Affiliated with

Also associated with

Rating

Botulinum toxin therapy for neuropsychiatric disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Botulinum toxin therapy for neuropsychiatric disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin therapy for neuropsychiatric disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3827973